Evidence map›Paper›PMID 40169760›Full record

Trial reportScientific reports2025

A double blinded randomized placebo trial of Bifidobacterium animalis subsp. lactis BLa80 on sleep quality and gut microbiota in healthy adults.

Yinhua Liu, Yanyan Chen, Qingya Zhang, Yanyan Zhang, Fei Xu

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Foods (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yinhua LiuCollege of Food Science and Technology, Henan University of Technology, 100, Lianhua Street, High-tech, Zhengzhou, 450001, People's Republic of China.
Yanyan ChenCollege of Food Science and Technology, Henan University of Technology, 100, Lianhua Street, High-tech, Zhengzhou, 450001, People's Republic of China.
Qingya ZhangCollege of Food Science and Technology, Henan University of Technology, 100, Lianhua Street, High-tech, Zhengzhou, 450001, People's Republic of China.
Yanyan ZhangDepartment of Food Quality and Safety, Shanghai Business School, Shanghai, 200235, China.
Fei XuCollege of Food Science and Technology, Henan University of Technology, 100, Lianhua Street, High-tech, Zhengzhou, 450001, People's Republic of China. xu.fei@haut.edu.cn.

Funding

Science and Technology Department of Henan Province 232300420207
6 · The paper itself

Abstract

Human sleep quality is intricately linked to gut health. Emerging research indicates that Bifidobacterium animalis subsp. lactis BLa80 has the potential to ameliorate gut microbiota dysbiosis. This randomized, placebo-controlled study evaluated the impact of BLa80 supplementation on sleep quality and gut microbiota in healthy individuals. One hundred and six participants were randomly assigned to receive either a placebo (maltodextrin) or BLa80 (maltodextrin + BLa80 at 10 billion CFU/day) for 8 weeks. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI), a validated tool consisting of 18 items assessing seven components of sleep quality over a one-month period, and the Insomnia Severity Index (ISI), a secondary measure of insomnia severity. Gut microbiota changes were assessed using 16S rRNA sequencing, while the in vitro gamma-aminobutyric acid (GABA) production capacity of BLa80 was analyzed by HPLC. After 8 weeks, the intervention group exhibited a significant reduction in the PSQI total score compared to the placebo group, suggesting improved sleep quality. While no significant changes in alpha diversity were noted, beta diversity differed markedly between groups. The gut microbiota predominantly consisted of Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Fusobacteria, collectively accounting for over 99.9% of the gut microbiota. Statistical analysis showed that BLa80 significantly decreased the relative abundance of Proteobacteria phylum and increased the abundance of Bacteroidetes, Fusicatenbacter, and Parabacteroides compared to placebo. PICRUSt2 analysis indicated noteworthy enhancements in the pathways of purine metabolism, glycolysis/gluconeogenesis, and arginine biosynthesis due to BLa80 intervention. Moreover, BLa80 demonstrated notable GABA production, potentially contributing to its effects on sleep quality modulation. These results demonstrate the ability of BLa80 to improve sleep quality through modulating gut microbiota and GABA synthesis, highlighting its potential as a beneficial probiotic strain.

Indexed as

Bifidobacterium animalisGastrointestinal MicrobiomeProbioticsSleep QualityAdultDouble-Blind MethodFemaleHealthy VolunteersHumansMaleMiddle AgedRNA, Ribosomal, 16SYoung AdultRNA, Ribosomal, 16SBifidobacterium animalis subsp. Lactis BLa80Gut microbiotaHealthy adultsPurine and pyrimidine metabolismSleep quality

Identifiers

PMID40169760
PMCPMC11961682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.